首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1919952

溶瘤病毒疗法市场规模、份额及成长分析（按病毒类型、癌症类型、治疗方法、给药途径、最终用户和地区划分）－2026-2033年产业预测

Oncolytic Virus Therapy Market Size, Share, and Growth Analysis, By Virus Type (Adenovirus, Herpes Simplex Virus), By Cancer Type, By Therapy Type, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月09日 | 出版商:

SkyQuest | 英文 184 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球溶瘤病毒疗法市场规模预计在 2024 年达到 4.114 亿美元，从 2025 年的 5.1713 亿美元增长到 2033 年的 32.2316 亿美元，在预测期（2026-2033 年）内复合年增长率为 25.7%。

市场分析表明，由于癌症病例的不断增加以及人们对溶瘤病毒治疗效果日益增长的兴趣，溶瘤病毒疗法行业预计将迎来显着增长。创新影像技术的进步，以及持续的研发投入，进一步提升了此治疗方法的吸引力。此外，科学突破与临床应用的整合有望推动该领域的投资和创新。医疗保健和生物技术行业的相关人员认识到溶瘤病毒疗法具有颠覆性的巨大潜力，这为市场的强劲扩张和肿瘤学新治疗方法的涌现提供了广阔前景。这种不断变化的市场格局预示着癌症治疗方法的变革性转变。

全球溶瘤病毒疗法市场驱动因素

全球癌症发生率的不断上升，使得人们迫切需要更具针对性和更有效的治疗方法，溶瘤病毒疗法的需求也因此显着增长。传统的治疗方法，例如化疗和放疗，由于其局限性，往往效果不佳，促使患者和医护人员寻求其他解决方案。溶瘤病毒疗法提供了一种全新的方法，它能够特异性攻击癌细胞，同时刺激免疫系统。这种双重作用不仅有助于摧毁癌细胞，还能增强人体对病毒和癌症的免疫反应，使其成为极具前景的治疗方法。

限制全球溶瘤病毒疗法市场的因素

溶瘤病毒疗法市场受到许多因素的限制，这些因素导致其高成本，包括复杂的基因工程流程、繁复的生产技术以及生产后必须立即处理的材料的严格储存要求。因此，这些经济障碍使得许多低收入患者无法负担治疗费用，限制了他们在註重成本的医疗保健系统中从这种创新治疗方法中获益的机会。这造成了治疗机会的不均等，并限制了溶瘤病毒疗法在不同人群中癌症治疗的潜在影响。

全球溶瘤病毒疗法市场趋势

基因工程的突破使得精准标靶化癌细胞并保护健康组织成为可能，显着推动了全球溶瘤病毒疗法市场的成长。研究人员正持续开发病毒改造技术，这些技术不仅能直接攻击肿瘤，还能透过整合细胞激素和查核点抑制剂来增强身体的免疫反应。先进技术的进步为溶瘤疗法带来了创新方法，为更有效的治疗方法铺平了道路，这些方案可在临床环境中即时调整。这一趋势反映了肿瘤学领域向个人化医疗的更广泛转变，并将溶瘤病毒疗法定位为癌症治疗领域一个充满希望的新前沿。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Amgen
SillaJen
PsiOxus Therapeutics
Transgene
Oncolytics Biotech
Replimune Group
Viralytics
Virotherapy Center
DNAtrix
Genelux
Turnstone Biologics
Vyriad
Oncorus
Lokon Pharma
Sorrento Therapeutics
BioVex
CG Oncology
ImmVirX
Hookipa Pharma
Theriva Biologics

结论与建议

简介目录

Product Code: SQMIG35H2403

Global Oncolytic Virus Therapy Market size was valued at USD 411.4 million in 2024 and is poised to grow from USD 517.13 million in 2025 to USD 3223.16 million by 2033, growing at a CAGR of 25.7% during the forecast period (2026-2033).

Market insights indicate that the oncolytic virus therapy industry is poised for significant growth due to an increasing prevalence of cancer cases and heightened interest in the therapeutic benefits of oncolytic viruses. The advancement of innovative imaging technologies, coupled with ongoing research and development efforts, is further enhancing the appeal of this treatment modality. Additionally, the convergence of scientific breakthroughs and clinical applications will likely drive investment and innovation within the sector. Stakeholders in the healthcare and biotechnology industries are recognizing the potential of oncolytic virus therapy as a game-changing approach, positioning the market for robust expansion and promising opportunities for novel therapeutics in oncology. This evolving landscape signals a transformative shift in cancer treatment methodologies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncolytic Virus Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncolytic Virus Therapy Market Segments Analysis

Global Oncolytic Virus Therapy Market is segmented by Virus Type, Cancer Type, Therapy Type, Route of Administration, End User and region. Based on Virus Type, the market is segmented into Adenovirus, Herpes Simplex Virus, Reovirus, Vaccinia Virus and Others. Based on Cancer Type, the market is segmented into Melanoma, Lung Cancer, Breast Cancer, Colorectal Cancer and Others. Based on Therapy Type, the market is segmented into Monotherapy and Combination Therapy. Based on Route of Administration, the market is segmented into Intratumoral and Intravenous. Based on End User, the market is segmented into Hospitals, Specialty Clinics and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Oncolytic Virus Therapy Market

The rising incidence of cancers globally is driving a substantial demand for oncolytic virus therapies, as there is a pressing need for more targeted and effective treatment options. Traditional treatment methods, like chemotherapy and radiation, often fall short due to their limitations, prompting patients and healthcare providers to look for alternative solutions. Oncolytic virus therapies offer a novel approach by specifically attacking cancer cells while simultaneously stimulating the immune system. This dual action not only helps in destroying the cancerous cells but also enhances the body's immune response against both the virus and the cancer, making it a promising therapeutic avenue.

Restraints in the Global Oncolytic Virus Therapy Market

The oncolytic virus therapy market is hindered by numerous factors leading to its elevated costs. These include the sophisticated processes involved in genetic engineering, intricate manufacturing techniques, and the strict storage requirements for the materials, which must be addressed immediately after production. Consequently, these financial obstacles restrict access for many patients in lower-income communities and curtail opportunities for individuals within cost-sensitive healthcare systems to benefit from this innovative treatment option. This situation creates a disparity in accessibility, limiting the potential impact of oncolytic virus therapies in addressing cancer across diverse populations.

Market Trends of the Global Oncolytic Virus Therapy Market

The Global Oncolytic Virus Therapy market is experiencing significant growth driven by breakthroughs in genetic engineering, which enable precise targeting of cancer cells while sparing healthy tissue. Researchers are increasingly able to modify viruses to not only attack tumors directly but also enhance the body's immune response through the incorporation of cytokines and checkpoint inhibitors. As advanced technologies evolve, they facilitate innovative approaches to oncolytic therapies, paving the way for more effective treatments that can be tailored in real-time within clinical settings. This trend reflects a broader shift towards personalized medicine in oncology, positioning oncolytic virus therapy as a promising frontier in cancer treatment.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment
Technology Assessment
Regulatory Landscape

Global Oncolytic Virus Therapy Market Size by Virus Type & CAGR (2026-2033)

Market Overview
Adenovirus
Herpes Simplex Virus
Reovirus
Vaccinia Virus
Others

Global Oncolytic Virus Therapy Market Size by Cancer Type & CAGR (2026-2033)

Market Overview
Melanoma
Lung Cancer
Breast Cancer
Colorectal Cancer
Others

Global Oncolytic Virus Therapy Market Size by Therapy Type & CAGR (2026-2033)

Market Overview
Monotherapy
Combination Therapy

Global Oncolytic Virus Therapy Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intratumoral
Intravenous

Global Oncolytic Virus Therapy Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Clinics
Research Institutes

Global Oncolytic Virus Therapy Market Size & CAGR (2026-2033)

North America (Virus Type, Cancer Type, Therapy Type, Route of Administration, End User)
- US
- Canada
Europe (Virus Type, Cancer Type, Therapy Type, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Virus Type, Cancer Type, Therapy Type, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Virus Type, Cancer Type, Therapy Type, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Virus Type, Cancer Type, Therapy Type, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SillaJen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PsiOxus Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Transgene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncolytics Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Replimune Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viralytics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Virotherapy Center
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DNAtrix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genelux
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Turnstone Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vyriad
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncorus
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lokon Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioVex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CG Oncology
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ImmVirX
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hookipa Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theriva Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments